Voyager Therapeutics (VYGR) EBITDA Margin (2015 - 2026)

Voyager Therapeutics has disclosed EBITDA Margin across 12 years of filings, most recently posting 824.75% for Q2 2026.

• In Q2 2026, EBITDA Margin fell 12042.0% year-over-year to 824.75%; the TTM figure through Jun 2026 stood at 339.32% (down 4970.0% YoY), while the FY2025 annual figure was 326.56%, down 22245.0% from the prior year.
• EBITDA Margin came in at 824.75% for Q2 2026 at Voyager Therapeutics, up from 1164.23% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 1584.71% in Q4 2022 to a low of 3244.68% in Q1 2022.
• Average EBITDA Margin over 5 years is 545.1%, with a median of 373.61% recorded in 2023.
• Year-over-year, EBITDA Margin slumped 285106 bps in 2022 and surged 332634 bps in 2023.
• Over 5 years, EBITDA Margin stood at 1584.71% in 2022, then tumbled by 96 bps to 60.03% in 2023, then tumbled by 1116 bps to 610.05% in 2024, then jumped by 68 bps to 195.17% in 2025, then slumped by 323 bps to 824.75% in 2026.
• Per Business Quant data, the three most recent EBITDA Margin figures were 824.75% in Q2 2026, 1164.23% in Q1 2026, and 195.17% in Q4 2025.